Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chiyoda-Ku, Tokyo, Japan, 102-8667
- MSD K.K.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Japanese male
- Have a legal representative who provides written informed consent for the trial on the participant's behalf
- Have a legal representative who is able to read, understand, and complete the vaccine report card
- Has not yet had coitarche and does not plan on becoming sexually active from Day 1 through Month 7 of the study
- Other inclusion criteria will be discussed with the investigator during screening
Exclusion Criteria:
- Currently enrolled in clinical studies of investigational agents
- History of known prior vaccination with an HPV vaccine or plans to receive one outside the study
- History of severe allergic reaction that required medical intervention
- Allergic to any vaccine component, including aluminum, yeast, or BENZONASE™
- Received immune globulin or blood-derived products in the past 6 months or plans to receive any before Month 7 of the study
- History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
- Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids
- Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections
- Ongoing alcohol or drug abuse within the past 12 months
- History of genital warts or a positive test for HPV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: V501
0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
|
Quadrivalent HPV [Type 6, 11, 16 and 18] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18
Time Frame: Four weeks postdose 3 (Month 7)
|
Antibodies to HPV Types 6, 11, 16, and 18 were measured using a competitive luminex immunoassay 4 weeks after 3rd vaccination (Month 7).
Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Seroconversion was defined as an anti-HPV 6 titer ≥20 mMU/mL, an anti-HPV 11 titer ≥16 mMU/mL, an anti-HPV 16 titer of ≥20 mMU/mL and an anti-HPV 18 titer of ≥24 mMU/mL.
|
Four weeks postdose 3 (Month 7)
|
|
Percentage of Participants With Elevated Oral Temperature (>=37.5° C)
Time Frame: Up to Day 5 after any vaccination
|
The parent/guardian of the participant was to record the participant's oral temperature in the evening after each study vaccination and daily for 4 days after each study vaccination.
Elevated temperature was defined as ≥99.5°F (≥37.5ºC).
The percentage of participants that had an elevated temperature was summarized.
|
Up to Day 5 after any vaccination
|
|
Percentage of Participants With an Injection-site Adverse Event
Time Frame: Up to Day 5 after any vaccination
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug.
An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure.
Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE.
The parent/guardian of the participant was to record the presence of any vaccination report card (VRC)-prompted injection-site AEs that occurred in the 5 days after any vaccination.
The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, and swelling) was summarized.
|
Up to Day 5 after any vaccination
|
|
Percentage of Participants With a Systemic Adverse Event
Time Frame: Up to Day 15 after any vaccination
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug.
An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure.
Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE.
The parent/guardian of the participant was to record the presence of any VRC-prompted systemic AEs that occurred in the 5 days after any vaccination.
The percentage of participants with a systemic AE was summarized.
|
Up to Day 15 after any vaccination
|
|
Percentage of Participants With a Serious Adverse Event
Time Frame: Up to Day 15 after any vaccination
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.
A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.
The percentage of participants that experienced 1 or more SAEs was summarized.
|
Up to Day 15 after any vaccination
|
|
Percentage of Participants With a Vaccine-related Serious Adverse Event
Time Frame: Up to 30 months
|
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.
A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.
The percentage of participants that experienced 1 or more SAEs that were considered at least possibly related to the study vaccine was summarized.
|
Up to 30 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18 Participants Aged 9 to 15 Years Versus Participants Aged 16 to 26 Years
Time Frame: Four weeks postdose 3 (Month 7)
|
Antibodies to HPV Types 6, 11, 16, and 18 were measured using a competitive luminex immunoassay.
Antibody titers were expressed mMU/mL.
GMTs obtained for each anti-HPV from this study were compared to each of the ant-HPV GMTs obtained in study V501-122 (NCT NCT01862874) in which Japanese males 16 to 26 years received V501 in the same 3 dose regimen, to test a hypothesis that would demonstrate non-inferiority.
|
Four weeks postdose 3 (Month 7)
|
|
Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18: Persistence at 18 Months
Time Frame: 12 months postdose 3 (18 months)
|
Antibodies to HPV Types 6, 11, 16, and 18 were measured using a competitive luminex immunoassay.
Antibody titers were expressed as mMU/mL.
|
12 months postdose 3 (18 months)
|
|
Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18: Persistence at 30 Months
Time Frame: 24 months postdose 3 (30 months)
|
Antibodies to HPV Types 6, 11, 16, and 18 were measured using a competitive luminex immunoassay.
Antibody titers were expressed as mMU/mL.
|
24 months postdose 3 (30 months)
|
|
Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: Persistence at 18 Months
Time Frame: 12 months postdose 3 (18 months)
|
Serum antibodies to HPV types were measured with a competitive luminex immunoassay.
The serostatus cutoffs (mMU/mL) for HPV types were as follows: HPV Type 6: ≥20; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24
|
12 months postdose 3 (18 months)
|
|
Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: Persistence at 30 Months
Time Frame: 24 months postdose 3 (30 months)
|
Serum antibodies to HPV types were measured with a competitive luminex immunoassay.
The serostatus cutoffs (mMU/mL) for HPV types were as follows: HPV Type 6: ≥20; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24.
|
24 months postdose 3 (30 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- V501-200
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.